Get to know our clinical trials
Ensayo aleatorizado controlado con placebo para evaluar la eficacia, seguridad y farmacocinética de baricitinib en niños y adolescentes con alopecia areata
THE MAIN REASON FOR PARTICIPATING IN THIS STUDY IS NOT TO PROVIDE TREATMENT FOR THE DISEASE, BUT TO CONTRIBUTE TO ANSWERING THE FOLLOWING SCIENTIFIC QUESTIONS: -HOW BARICITINIB (LY3009104) COMPARES TO PLACEBO IN HELPING CHILDREN AND ADOLESCENTS SUFFERING FROM ALOPECIA AREATA. -THE SAFETY OF BARICITINIB AND ANY SIDE EFFECTS THAT MAY OCCUR WHEN TAKING IT. IN SHORT, THIS STUDY WILL HELP US LEARN MORE ABOUT A STUDY DRUG CALLED BARICITINIB. WE WANT TO FIND OUT IF IT HELPS CHILDREN WHO HAVE ALOPECIA AREATA, A'SI AS WELL AS IF THIS DRUG CAUSES ANY UNWANTED REACTIONS.
Technical Summary
- PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF BARICITINIB IN CHILDREN AGED 6 YEARS TO LESS THAN 18 YEARS WITH ALOPECIA AREATA.
- Code EudraCT: 2022-502700-78-00
- Protocol number: I4V-MC-JAIO
- Promoter: Lilly
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.